Apatinib is a novel and highly selective inhibitor of the VEGFR2 tyrosine kinase, which blocks the downstream signal transduction of VEGFR2 at the cellular level.[23] Apatinib has been proven to be a safe and effective drug in patients with advanced gastric cancer. The gene discussed is KDR; the disease is gastric cancer.